Last updated: 2026-09-16 09:06:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Replimune Group, Inc. (REPL) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $13,05, with a market capitalisation of $1,24B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1,50 to $16,33. This page covers its latest market performance, valuation, price trends and company information.
$1,24B | |
$13,01 | |
$54,85 | |
$1,50 | |
$13,03 | |
15,00 | |
4,53M | |
-- | |
$16,33 | |
$1,50 | |
-- | |
-- |
Replimune Group, Inc. (REPL) is trading at $13,05 in pre-market trading as of 2026-09-16 08:01:00, up 0,15% ($0,02) from the previous close of $13,03
Pre-market trading shows how investors are pricing REPL before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Over the past seven days, Replimune Group, Inc. (REPL) moved from $15,04 to $13,05, representing a decline of 13,24% ($1,99).
The stock traded between $12,40 and $15,33 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 2,25 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 77,9%
REPL is currently trading at $13,05, placing it 77,9% of the way from its 52-week low of $1,50 to its 52-week high of $16,33. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 465 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Replimune Group, Inc. (REPL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.